Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial

被引:105
|
作者
Liu, You-Ping [1 ,2 ]
Wen, Yi-Hui [1 ]
Tang, Jun [4 ]
Wei, Yi [1 ]
You, Rui [2 ]
Zhu, Xiao-Lin [1 ]
Li, Jian [1 ]
Chen, Lin [1 ]
Ling, Li [6 ,7 ]
Zhang, Ning [5 ]
Zou, Xiong [2 ]
Hua, Yi-Jun [2 ]
Chen, You-Mou [4 ]
Chen, Lei [3 ]
Lu, Li-Xia [3 ]
Chen, Ming-Yuan [2 ]
Wen, Wei-Ping [1 ,8 ]
机构
[1] Sun Yat Sen Univ, Otorhinolaryngol Inst, Affiliated Hosp 1, Guangzhou Key Lab Otorhinolaryngol,Dept Otolaryng, Guangzhou 510080, Peoples R China
[2] Sun Yat Sen Univ, State Key Lab Oncol South China,Canc Ctr, Collaborat Innovat Ctr Canc Med,Dept Nasopharynge, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, State Key Lab Oncol South China,Canc Ctr, Collaborat Innovat Ctr Canc Med,Dept Radiat Oncol, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, Guangzhou, Peoples R China
[4] First Peoples Hosp Foshan, Dept Otolaryngol, Foshan, Peoples R China
[5] First Peoples Hosp Foshan, Dept Radiat Oncol, Foshan, Peoples R China
[6] Sun Yat Sen Univ, Dept Med Stat, Sch Publ Hlth, Guangzhou, Peoples R China
[7] Sun Yat Sen Univ, Ctr Migrant Hlth Policy, Guangzhou, Peoples R China
[8] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Otolaryngol, Guangzhou, Peoples R China
来源
LANCET ONCOLOGY | 2021年 / 22卷 / 03期
基金
中国国家自然科学基金;
关键词
3-DIMENSIONAL CONFORMAL RADIOTHERAPY; CONCURRENT CHEMORADIOTHERAPY; RADIATION-THERAPY; CHEMOTHERAPY; REIRRADIATION; CANCER; EVENTS;
D O I
10.1016/S1470-2045(20)30673-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The role of surgery compared with reirradiation in the primary treatment of patients with resectable, locally recurrent nasopharyngeal carcinoma (NPC) who have previously received radiotherapy is a matter of debate. In this trial, we compared the efficacy and safety outcomes of salvage endoscopic surgery versus intensity-modulated radiotherapy (IMRT) in patients with resectable locally recurrent NPC. Methods This multicentre, open-label, randomised, controlled, phase 3 trial was done in three hospitals in southern China. We included patients aged 18-70 years with a Karnofsky Performance Status score of at least 70 who were histopathologically diagnosed with undifferentiated or differentiated, non-keratinising, locally recurrent NPC with tumours confined to the nasopharyngeal cavity, the post-naris or nasal septum, the superficial parapharyngeal space, or the base wall of the sphenoid sinus. Eligible patients were randomly assigned (1:1) to receive either endoscopic nasopharyngectomy (ENPG group) or IMRT (IMRT group). Randomisation was done manually using a computer-generated random number code and patients were stratified by treatment centre. Treatment group assignment was not masked. The primary endpoint was overall survival, compared between the groups at 3 years. Efficacy analyses were done by intention to treat. Safety analysis was done in patients who received treatment according to the treatment they actually received. This trial was prospectively registered at the Chinese Clinical Trial Registry, ChiCTRTRC-11001573, and is currently in follow-up. Findings Between Sept 30, 2011, and Jan 16, 2017, 200 eligible patients were randomly assigned to receive either ENPG (n=100) or IMRT (n=100). At a median follow-up of 56.0 months (IQR 42.0-69.0), 74 patients had died (29 [29%] of 100 patients in the ENPG group and 45 [45%] of 100 patients in the IMRT group). The 3-year overall survival was 85.8% (95% CI 78.9-92.7) in the ENPG group and 68.0% (58.6-77.4) in the IMRT group (hazard ratio 0.47, 95% CI 0.29-0.76; p=0.0015). The most common grade 3 or worse radiation-related late adverse event was pharyngeal mucositis (in five [5%] of 99 patients who underwent ENPG and 26 [26%] of 101 patients who underwent IMRT). Five [5%] of the 99 patients who underwent ENPG and 20 [20%] of the 101 patients who underwent IMRT died due to late toxic effects specific to radiotherapy; attribution to previous radiotherapy or trial radiotherapy is unclear due to the long-term nature of radiation-related toxicity. Interpretation Endoscopic surgery significantly improved overall survival compared with IMRT in patients with resectable locally recurrent NPC. These results suggest that ENPG could be considered as the standard treatment option for this patient population, although long-term follow-up is needed to further determine the efficacy and toxicity of this strategy. (C) 2021 Elsevier Ltd. All rights reserved.
引用
收藏
页码:381 / 390
页数:10
相关论文
共 50 条
  • [21] Minimally invasive surgery alone compared with intensity-modulated radiotherapy for primary stage I nasopharyngeal carcinoma
    Liu, You-Ping
    Lv, Xing
    Zou, Xiong
    Hua, Yi-Jun
    You, Rui
    Yang, Qi
    Xia, Le
    Guo, Shao-Yan
    Hu, Wen
    Zhang, Meng-Xia
    Chen, Si-Yuan
    Lin, Mei
    Xie, Yu-Long
    Liu, Li-Zhi
    Sun, Rui
    Huang, Pei-Yu
    Fan, Wei
    Guo, Xiang
    Hong, Ming-Huang
    Chen, Ming-Yuan
    CANCER COMMUNICATIONS, 2019, 39 (01)
  • [22] Hyperfractionation compared to standard fractionation in intensity-modulated radiation therapy for patients with locally advanced recurrent nasopharyngeal carcinoma
    Lee, Victor H. F.
    Kwong, Dora L. W.
    Leung, To-Wai
    Ng, Sherry C. Y.
    Lam, Ka-On
    Tong, Chi-Chung
    Sze, Chun-Kin
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2017, 274 (02) : 1067 - 1078
  • [23] Hyperfractionation compared to standard fractionation in intensity-modulated radiation therapy for patients with locally advanced recurrent nasopharyngeal carcinoma
    Victor H. F. Lee
    Dora L. W. Kwong
    To-Wai Leung
    Sherry C. Y. Ng
    Ka-On Lam
    Chi-Chung Tong
    Chun-Kin Sze
    European Archives of Oto-Rhino-Laryngology, 2017, 274 : 1067 - 1078
  • [24] Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma
    Ya Hua Zhong
    Jing Dai
    Xiao Yong Wang
    Cong Hua Xie
    Gang Chen
    Lei Zeng
    Yun Feng Zhou
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1577 - 1583
  • [25] Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma
    Zhong, Ya Hua
    Dai, Jing
    Wang, Xiao Yong
    Xie, Cong Hua
    Chen, Gang
    Zeng, Lei
    Zhou, Yun Feng
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (06) : 1577 - 1583
  • [26] Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
    Lombardi, Giuseppe
    De Salvo, Gian Luca
    Brandes, Alba Ariela
    Eoli, Marica
    Ruda, Roberta
    Faedi, Marina
    Lolli, Ivan
    Pace, Andrea
    Daniele, Bruno
    Pasqualetti, Francesco
    Rizzato, Simona
    Bellu, Luisa
    Pambuku, Ardi
    Farina, Miriam
    Magni, Giovanna
    Indraccolo, Stefano
    Gardiman, Marina Paola
    Soffietti, Riccardo
    Zagonel, Vittorina
    LANCET ONCOLOGY, 2019, 20 (01): : 110 - 119
  • [27] Subcuticular sutures versus staples for skin closure after open gastrointestinal surgery: a phase 3, multicentre, open-label, randomised controlled trial
    Tsujinaka, Toshimasa
    Yamamoto, Kazuyoshi
    Fujita, Junya
    Endo, Shunji
    Kawada, Junji
    Nakahira, Shin
    Shimokawa, Toshio
    Kobayashi, Shogo
    Yamasaki, Makoto
    Akamaru, Yusuke
    Miyamoto, Atsushi
    Mizushima, Tsunekazu
    Shimizu, Junzo
    Umeshita, Koji
    Ito, Toshinori
    Doki, Yuichiro
    Mori, Masaki
    LANCET, 2013, 382 (9898): : 1105 - 1112
  • [28] Effect of Total Dose and Fraction Size on Survival of Patients With Locally Recurrent Nasopharyngeal Carcinoma Treated With Intensity-Modulated Radiotherapy: A Phase 2, Single-Center, Randomized Controlled Trial
    Tian, Yun-ming
    Zhao, Chong
    Guo, Ying
    Huang, Ying
    Huang, Shao-Min
    Deng, Xiao-Wu
    Lin, Cheng-Guang
    Lu, Tai-xiang
    Han, Fei
    CANCER, 2014, 120 (22) : 3502 - 3509
  • [29] Safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity-modulated radiotherapy for resectable pancreatic cancer: A prospective, open-label, phase II study
    Masui, Toshihiko
    Nagai, Kazuyuki
    Anazawa, Takayuki
    Kasai, Yosuke
    Yogo, Akitada
    Yoshimura, Michio
    Mizowaki, Takashi
    Uza, Norimitsu
    Fukuda, Akihisa
    Matsumoto, Shigemi
    Kanai, Masashi
    Isoda, Hiroyoshi
    Kawaguchi, Yoshiya
    Uemoto, Shinji
    Hatano, Etsuro
    CANCER MEDICINE, 2023, 12 (18): : 18611 - 18621
  • [30] Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
    Hauschild, Axel
    Grob, Jean-Jacques
    Demidov, Lev V.
    Jouary, Thomas
    Gutzmer, Ralf
    Millward, Michael
    Rutkowski, Piotr
    Blank, Christian U.
    Miller, Wilson H., Jr.
    Kaempgen, Eckhart
    Martin-Algarra, Salvador
    Karaszewska, Boguslawa
    Mauch, Cornelia
    Chiarion-Sileni, Vanna
    Martin, Anne-Marie
    Swann, Suzanne
    Haney, Patricia
    Mirakhur, Beloo
    Guckert, Mary E.
    Goodman, Vicki
    Chapman, Paul B.
    LANCET, 2012, 380 (9839): : 358 - 365